A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Five Dose Regimens of Aes-103 Given for 28 Days to Subjects with Stable Sickle Cell Disease

Trial Profile

A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Five Dose Regimens of Aes-103 Given for 28 Days to Subjects with Stable Sickle Cell Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs BAX 555 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AesRx; Baxalta
  • Most Recent Events

    • 23 Sep 2015 According to a report by Guy's and Thomas' NHS Foundation Trust, this trial did not meet its benchmark because of sponsor delays (www.guysandstthomas.nhs.uk/resources/research/70-day-benchmark.xls).
    • 10 Aug 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 02 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top